These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 38438251)
1. SMYD4 monomethylates PRMT5 and forms a positive feedback loop to promote hepatocellular carcinoma progression. Zhou Z; Chen Z; Zhou Q; Meng S; Shi J; Mui S; Jiang H; Lin J; He G; Li W; Zhang J; Wang J; He C; Yan Y; Xiao Z Cancer Sci; 2024 May; 115(5):1587-1601. PubMed ID: 38438251 [TBL] [Abstract][Full Text] [Related]
2. Circ-PRMT5 enhances the proliferation, migration and glycolysis of hepatoma cells by targeting miR-188-5p/HK2 axis. Ding Z; Guo L; Deng Z; Li P Ann Hepatol; 2020; 19(3):269-279. PubMed ID: 32089501 [TBL] [Abstract][Full Text] [Related]
3. PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma. Jiang H; Zhu Y; Zhou Z; Xu J; Jin S; Xu K; Zhang H; Sun Q; Wang J; Xu J Cancer Med; 2018 Mar; 7(3):869-882. PubMed ID: 29441724 [TBL] [Abstract][Full Text] [Related]
4. PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma. Yang H; Zhao X; Zhao L; Liu L; Li J; Jia W; Liu J; Huang G Oncotarget; 2016 Nov; 7(44):72131-72147. PubMed ID: 27708221 [TBL] [Abstract][Full Text] [Related]
5. Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin. Zhang B; Dong S; Li Z; Lu L; Zhang S; Chen X; Cen X; Wu Y J Transl Med; 2015 Nov; 13():349. PubMed ID: 26541651 [TBL] [Abstract][Full Text] [Related]
6. Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma. Luo Y; Gao Y; Liu W; Yang Y; Jiang J; Wang Y; Tang W; Yang S; Sun L; Cai J; Guo X; Takahashi S; Krausz KW; Qu A; Chen L; Xie C; Gonzalez FJ Hepatology; 2021 Oct; 74(4):1932-1951. PubMed ID: 33896016 [TBL] [Abstract][Full Text] [Related]
7. Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling. Jing P; Zhao N; Ye M; Zhang Y; Zhang Z; Sun J; Wang Z; Zhang J; Gu Z Cancer Lett; 2018 Jul; 427():38-48. PubMed ID: 29679612 [TBL] [Abstract][Full Text] [Related]
8. Metadherin-PRMT5 complex enhances the metastasis of hepatocellular carcinoma through the WNT-β-catenin signaling pathway. Zhu K; Peng Y; Hu J; Zhan H; Yang L; Gao Q; Jia H; Luo R; Dai Z; Tang Z; Fan J; Zhou J Carcinogenesis; 2020 Apr; 41(2):130-138. PubMed ID: 31498866 [TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway. Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171 [TBL] [Abstract][Full Text] [Related]
10. Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells. Jeon JY; Lee JS; Park ER; Shen YN; Kim MY; Shin HJ; Joo HY; Cho EH; Moon SM; Shin US; Park SH; Han CJ; Choi DW; Gu MB; Kim SB; Lee KH Oncol Rep; 2018 Jul; 40(1):536-544. PubMed ID: 29749478 [TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA CCDC183-AS1 acts AS a miR-589-5p sponge to promote the progression of hepatocellular carcinoma through regulating SKP1 expression. Zhu H; Zhang H; Pei Y; Liao Z; Liu F; Su C; Liu Y; Dong R; Song J; Zhang X; Fan Y; Liang H; Zhang B; Chen X J Exp Clin Cancer Res; 2021 Feb; 40(1):57. PubMed ID: 33541391 [TBL] [Abstract][Full Text] [Related]
12. Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α. Zheng BN; Ding CH; Chen SJ; Zhu K; Shao J; Feng J; Xu WP; Cai LY; Zhu CP; Duan W; Ding J; Zhang X; Luo C; Xie WF Theranostics; 2019; 9(9):2606-2617. PubMed ID: 31131056 [No Abstract] [Full Text] [Related]
13. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression. Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859 [No Abstract] [Full Text] [Related]
14. The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy. Shimizu D; Kanda M; Sugimoto H; Shibata M; Tanaka H; Takami H; Iwata N; Hayashi M; Tanaka C; Kobayashi D; Yamada S; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y Int J Oncol; 2017 Feb; 50(2):381-386. PubMed ID: 28101581 [TBL] [Abstract][Full Text] [Related]
15. microRNA-93-5p promotes hepatocellular carcinoma progression via a microRNA-93-5p/MAP3K2/c-Jun positive feedback circuit. Shi X; Liu TT; Yu XN; Balakrishnan A; Zhu HR; Guo HY; Zhang GC; Bilegsaikhan E; Sun JL; Song GQ; Weng SQ; Dong L; Ott M; Zhu JM; Shen XZ Oncogene; 2020 Aug; 39(35):5768-5781. PubMed ID: 32719439 [TBL] [Abstract][Full Text] [Related]
16. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis. Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188 [TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA AGAP2-AS1, functioning as a competitive endogenous RNA, upregulates ANXA11 expression by sponging miR-16-5p and promotes proliferation and metastasis in hepatocellular carcinoma. Liu Z; Wang Y; Wang L; Yao B; Sun L; Liu R; Chen T; Niu Y; Tu K; Liu Q J Exp Clin Cancer Res; 2019 May; 38(1):194. PubMed ID: 31088485 [TBL] [Abstract][Full Text] [Related]
18. A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression. Chen H; Lorton B; Gupta V; Shechter D Oncogene; 2017 Jan; 36(3):373-386. PubMed ID: 27270440 [TBL] [Abstract][Full Text] [Related]
19. Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5. Tian Y; Yang W; Yang R; Zhang Q; Hao L; Bian E; Yang Y; Huang X; Wu Y; Zhang B Toxicol Appl Pharmacol; 2022 Jan; 435():115829. PubMed ID: 34919946 [TBL] [Abstract][Full Text] [Related]
20. PRMT2 accelerates tumorigenesis of hepatocellular carcinoma by activating Bcl2 via histone H3R8 methylation. Hu G; Yan C; Xie P; Cao Y; Shao J; Ge J Exp Cell Res; 2020 Sep; 394(2):112152. PubMed ID: 32574605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]